Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Revenue | $2,263,576,000 |
| Net Income | $858,983,000 |
| Free Cash Flow | $2,768,986,000 |
| Book Value / Share | $23.19 |
| Total Liabilities | $7,880,349,000 |
| Total Equity | $6,946,581,000 |
| Debt / Equity | 1.10 |
| Current Ratio | 1.44 |
| Interest Coverage | 5.73 |
| Working Capital | $548,523,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | 13.24 |
| Industry P/E | N/A |
| Forward P/E | 8.24 |
| P/B | 1.64 |
| Price / Sales | 5.03 |
| P / FCF | 4.11 |
| EV / EBITDA | 11.60 |
| Graham Number | $25.98 |
| DCF (placeholder) | — |
| Gross Margin | 100.00% |
| Operating Margin | 57.10% |
| Net Margin | 37.95% |
| ROIC | 7.19% |
| Asset Turnover | 0.12 |
| RSI (14) | 52.59 |
| SMA 50 | 36.10 |
| SMA 200 | 33.73 |
| MACD | -0.00 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO (1964) |
| Mr. Terrance P. Coyne | Executive VP & CFO (—) |
| Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer (1960) |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments (1976) |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel (—) |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments (—) |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer (—) |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer (1971) |
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.
Royalty Pharma (RPRX) has recently caught investors’ attention as its stock movement stands out in a mixed healthcare sector. With revenue showing a steady trajectory and a positive annual trend, the company’s profile appears increasingly attractive to long-term watchers. See our latest analysis for Royalty Pharma. Royalty Pharma’s share price has gained strong momentum this year, with a year-to-date return of nearly 40% and a one-year total shareholder return of almost 33%. Although recent...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 8.4% gain for healthcare stocks has fallen short of the S&P 500’s 22.7% rise.